• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KKR-led Consortium Drives Further Investment in Sylvan

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance
    Get the next $KKR alert in real time by email

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/

    Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential of fungal systems to create sustainable solutions to address global challenges in food, health, agriculture, and materials. Today, the Company operates multiple production facilities around the world and serves customers across 65 countries.

    This latest investment marks KKR's continued commitment to supporting Sylvan's next phase of expansion, including increasing production capacity, strengthening R&D capabilities, advancing new high-growth product categories, and deepening the Company's presence across Asia's rapidly industrializing mushroom and bio-products markets.

    The KKR-led investment also included commitments from global investors, including TPG NewQuest, who served as lead investor in a GP-led transaction alongside KKR to support Sylvan, in addition to Ping'An Capital, China Post Insurance, Schroders Capital and Tsao Pao Chee. KKR is making its investment through its international and domestic funds, including its first Renminbi-denominated fund, which was established to facilitate investment by local investors.

    Chris Sun, Partner and Head of China Private Equity at KKR, said: "Sylvan has delivered sustained growth under our strategic partnership, including strong expansion and advances in R&D and strategic acquisitions. We have worked closely with management to broaden Sylvan's role in the global fungal biotechnology sector and beyond. KKR is pleased to welcome new investors from overseas and China to join us in supporting Sylvan to expand its platform and global reach."

    Jackie Qi, CEO of Sylvan, said: "KKR has been a trusted partner for Sylvan through our development, and we are pleased to have their continued support. This investment allows us to accelerate our ambition to become a global leader in fungal biotechnology solutions across strategies and regions. With the support and expertise of our investors, we have faith in Sylvan's next phase of growth."

    About Sylvan

    Sylvan is a fungal biotechnology company, unlocking the incredible potential of the Earth's fungi systems. We believe these resilient fungi, having evolved over millions of years, hold the key to overcoming many of the problems our planet faces today and into the future. Our goal is simple: harness the power of fungi and create sustainable solutions to address global challenges in food, health, agriculture, and materials.

    About KKR

    KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260120305013/en/

    For more information, please contact:

    Sylvan

    Erica Wang

    Erica.Wang@sylvaninc.com

    KKR

    Wei Jun Ong

    Media@kkr.com

    Get the next $KKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KKR

    DatePrice TargetRatingAnalyst
    2/24/2026$137.00Outperform
    RBC Capital Mkts
    1/28/2026$144.00Hold → Buy
    HSBC Securities
    1/14/2026$131.00Buy → Hold
    TD Cowen
    12/11/2025$176.00Buy
    UBS
    7/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    7/9/2025$142.00Buy → Hold
    HSBC Securities
    6/30/2025$150.00Overweight
    Piper Sandler
    5/14/2025$150.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $KKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barakett Timothy R bought $4,723,500 worth of shares (50,000 units at $94.47) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/5/26 7:30:13 PM ET
    $KKR
    Investment Managers
    Finance

    Director Dillon Mary N bought $2,021,586 worth of shares (22,225 units at $90.96) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:01 PM ET
    $KKR
    Investment Managers
    Finance

    Co-Chief Executive Officer Bae Joseph Y bought $4,428,000 worth of shares (50,000 units at $88.56) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Issuer)

    3/3/26 4:34:04 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on KKR with a new price target

    RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00

    2/24/26 7:55:00 AM ET
    $KKR
    Investment Managers
    Finance

    KKR upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00

    1/28/26 7:11:28 AM ET
    $KKR
    Investment Managers
    Finance

    KKR downgraded by TD Cowen with a new price target

    TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00

    1/14/26 8:26:34 AM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Alternative Assets Llc acquired $2,422,339 worth of Class I Common Stock (105,871 units at $22.88) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    7/2/26 4:05:37 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Alternative Assets Llc acquired $1,523,312 worth of Class I Common Stock (65,491 units at $23.26) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    6/2/26 4:05:53 PM ET
    $KKR
    Investment Managers
    Finance

    Large owner Kkr Alternative Assets Llc acquired $1,476,681 worth of Class I Common Stock (63,459 units at $23.27) (SEC Form 4)

    4 - KKR & Co. Inc. (0001404912) (Reporting)

    5/4/26 4:05:48 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KKR Appoints Former Manulife CEO Roy Gori as Senior Advisor

    KKR, a leading global investment firm, today announced the appointment of Roy Gori, former President and Chief Executive Officer of Manulife, as a Senior Advisor to the firm. Mr. Gori, an accomplished leader in the global insurance and financial services industry, will advise KKR on strategic opportunities across global financial services and insurance with a focus on Asia Pacific and international markets. He will provide strategic counsel across insurance, wealth management, banking, distribution, and related financial services platforms. "We are pleased to welcome Roy to KKR as a Senior Advisor," said Joe Bae and Scott Nuttall, Co-Chief Executive Officers of KKR. "Roy is one of the mos

    7/21/26 6:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    Thomson Reuters and KKR Announce Joint Venture for Thomson Reuters Global Print Business

    TORONTO and NEW YORK, July 14, 2026 /CNW/ -- Thomson Reuters Corporation (TSX/Nasdaq: TRI) today announced that it has signed a definitive agreement to enter into a joint venture with KKR, a leading global investment firm. As part of the transaction, Thomson Reuters will sell a 51% stake in its Global Print business to capital accounts advised by KKR. Thomson Reuters will receive approximately $500 million in gross proceeds at closing and will retain a 49% equity interest in the joint venture. Thomson Reuters will also maintain intellectual property rights and full editorial control over its content portfolio. This new joint venture will hold an exclusive license to distribute the content in

    7/14/26 7:00:00 AM ET
    $TRI
    $KKR
    Publishing
    Consumer Discretionary
    Investment Managers
    Finance

    Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

    Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside Spero updates its cash runway guidance into the second half of 2029 CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) --  Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healt

    7/14/26 6:02:00 AM ET
    $SPRO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $KKR
    SEC Filings

    View All

    KKR & Co. Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/29/26 4:16:25 PM ET
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - KKR & Co. Inc. (0001404912) (Filer)

    5/28/26 4:15:25 PM ET
    $KKR
    Investment Managers
    Finance

    SEC Form S-3ASR filed by KKR & Co. Inc.

    S-3ASR - KKR & Co. Inc. (0001404912) (Filer)

    5/11/26 5:06:43 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Financials

    Live finance-specific insights

    View All

    FSK Announces Earnings Release and Conference Call Schedule for Second Quarter 2026

    PHILADELPHIA and NEW YORK, July 9, 2026 /PRNewswire/ -- FS KKR Capital Corp. (NYSE:FSK) announced today plans to release its second quarter 2026 results before the opening of trading on the New York Stock Exchange on Thursday, August 6, 2026. FSK will host its second quarter 2026 results conference call via live webcast on Thursday, August 6, 2026 at 9:00 a.m. (Eastern Time). All interested parties are welcome to participate and can access the live webcast from the For Investors section of FSK's website at www.fskkrcapitalcorp.com under Events & Presentations or through the foll

    7/9/26 4:20:00 PM ET
    $FSK
    $KKR
    Investment Managers
    Finance

    KKR & Co. Inc. to Announce Second Quarter 2026 Results

    KKR & Co. Inc. (NYSE:KKR) announced today that it plans to release its financial results for the second quarter 2026 on Thursday, July 30, 2026, before the opening of trading on the New York Stock Exchange.A conference call to discuss KKR’s financial results will be held on Thursday, July 30, 2026 at 9:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Center section of KKR’s website at https://ir.kkr.com/events-presentations/. A replay of the live broadcast will be avail

    7/1/26 4:15:00 PM ET
    $KKR
    Investment Managers
    Finance

    BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

    - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigr

    7/1/26 7:30:00 AM ET
    $BBIO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $KKR
    Leadership Updates

    Live Leadership Updates

    View All

    KKR Appoints Former Manulife CEO Roy Gori as Senior Advisor

    KKR, a leading global investment firm, today announced the appointment of Roy Gori, former President and Chief Executive Officer of Manulife, as a Senior Advisor to the firm. Mr. Gori, an accomplished leader in the global insurance and financial services industry, will advise KKR on strategic opportunities across global financial services and insurance with a focus on Asia Pacific and international markets. He will provide strategic counsel across insurance, wealth management, banking, distribution, and related financial services platforms. "We are pleased to welcome Roy to KKR as a Senior Advisor," said Joe Bae and Scott Nuttall, Co-Chief Executive Officers of KKR. "Roy is one of the mos

    7/21/26 6:30:00 PM ET
    $KKR
    Investment Managers
    Finance

    KKR Launches Allyntra, an Engineered Solutions Platform for Medical Technology and Precision Industries

    Robbie Atkinson appointed as CEO and Brian Highley appointed as Chairman KKR today announced the launch of Allyntra ("Allyntra" or the "Company"), a newly formed precision-engineered solutions platform serving medical technology and other precision end markets. Allyntra builds on KKR’s existing investment in Precipart through its Health Care Strategic Growth Fund II, with Precipart serving as one of the foundational businesses within the platform. KKR is committing meaningful additional capital to support Allyntra’s growth by acquiring and integrating complementary best-in-class businesses and through continued investment in innovation and commercial expansion. This press release feature

    7/9/26 6:59:00 AM ET
    $KKR
    $PRM
    Investment Managers
    Finance
    Major Chemicals
    Industrials

    KKR-led Consortium Drives Further Investment in Sylvan

    Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential

    1/20/26 8:02:00 PM ET
    $KKR
    Investment Managers
    Finance

    $KKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/12/24 3:50:17 PM ET
    $KKR
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by KKR & Co. Inc.

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    11/4/24 11:48:27 AM ET
    $KKR
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by KKR & Co. Inc. (Amendment)

    SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)

    2/13/24 6:32:37 PM ET
    $KKR
    Investment Managers
    Finance